Lipid-Lowering Therapy and Progression of Coronary Atherosclerosis


PLAC 1 is a double-blind randomized placebo-controlled trial assessing the<lb>efficacy of monotherapy with an HMG-CoA reductase inhibitor (pravastatin) in<lb>altering the atherosclerotic process. This trial was an angiographic trial under-<lb>taken in the United States and was completed in early 1994. Despite the fact that<lb>angiographic endpoints were the… (More)
DOI: 10.1007/978-94-009-0143-8

Cite this paper

@inproceedings{REIBER1996LipidLoweringTA, title={Lipid-Lowering Therapy and Progression of Coronary Atherosclerosis}, author={J.H.C. REIBER and J. Wouter Jukema and A. J. van Boven and J.H.e. Reiber and A. H. Zwinderman}, booktitle={Developments in Cardiovascular Medicine}, year={1996} }